The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.
Diabetes Ther
; 13(3): 489-503, 2022 Mar.
Article
in En
| MEDLINE
| ID: mdl-35187628
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Guideline
/
Health_economic_evaluation
/
Prognostic_studies
Aspects:
Patient_preference
Language:
En
Journal:
Diabetes Ther
Year:
2022
Document type:
Article
Affiliation country:
Dinamarca
Country of publication:
Estados Unidos